Impact Factor 2.349 | CiteScore 2.20
More on impact ›

Perspective ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pediatr. | doi: 10.3389/fped.2019.00428

Perspective: Using Bronchiectasis Action Management Plans for children with bronchiectasis – can it improve clinical care?

 Kobi L. Schutz1, 2*, Julie Marchant3,  Anne B. Chang1, 3, Catherine Turner2, Mark Chatfield4 and  Gabrielle B. McCallum1
  • 1Child Health Division, Menzies School of Health Research, Charles Darwin University, Australia
  • 2College of Nursing and Midwifery, Charles Darwin University, Australia
  • 3Department of Respiratory and Sleep Medicine, Centre for Children's Health Research, Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia
  • 4Centre for Health Services Research, University of Queensland, Australia


While once thought to be rare, bronchiectasis has been increasing globally over the last 15-years. Bronchiectasis is a major contributor to chronic lung morbidity and mortality but remains a neglected disease in respiratory health globally. Currently, few high-level evidence-based management strategies are available for children with bronchiectasis. Strategies to improve clinical outcomes associated with exacerbations are important. In other respiratory conditions such as asthma and chronic obstructive pulmonary disease, use of personalized written management plans have been shown to improve clinical outcomes. Personalized management plans have also been recommended as part of treatment plans in adults with bronchiectasis. We thus undertook a review of the current literature, to determine available evidence, to establish whether a personalized written bronchiectasis action management plan (BAMP) improves clinical outcomes in children with bronchiectasis. Our search identified 43 articles; 16 duplicates were removed and a further 23 were excluded on titles and abstracts alone. Four full text articles were reviewed but excluded. In the absence of any published studies, it remains unknown whether the use of BAMP is beneficial for improving clinical outcomes for children with bronchiectasis. These results have highlighted this clinical gap and identified the need for high-quality research to inform practice. Until high-quality evidence is available, clinicians are advised to adhere to current national and/or international guidelines.

Keywords: Children, Bronchiectasis, management plan, action plan, Randomised controlled clinical trial (RCT), clinical trials

Received: 19 Aug 2019; Accepted: 07 Oct 2019.

Copyright: © 2019 Schutz, Marchant, Chang, Turner, Chatfield and McCallum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mrs. Kobi L. Schutz, Menzies School of Health Research, Charles Darwin University, Child Health Division, Darwin, 0909, Northern Territory, Australia,